Current Gastroenterology Reports

, 15:311

Novel Targets for Inflammatory Bowel Disease Therapeutics

Inflammatory Bowel Disease (SB Hanauer, Section Editor)

DOI: 10.1007/s11894-012-0311-3

Cite this article as:
Löwenberg, M. & D’Haens, G. Curr Gastroenterol Rep (2013) 15: 311. doi:10.1007/s11894-012-0311-3
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease


In recent years, many new agents have been evaluated for the treatment of inflammatory bowel disease. In this paper, we critically review recently published literature about these novel therapies, which have been the result of extensive research identifying molecular targets. Of the various biologicals and small molecules that have recently been tested in clinical trials, several demonstrated clinical efficacy with a tolerable safety profile. We discuss a number of them with specific focus on vedolizumab, a monoclonal antibody directed against the alpha4beta7 integrin on lymphocytes, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, and tofacitinib, a small molecule targeting Janus-activated kinase. Most likely, these three agents will find their way to the market and offer significant therapeutic alternatives for the management of Crohn’s disease and/or ulcerative colitis.


Inflammatory bowel disease (IBD)Crohn’s disease (CD)Ulcerative colitis (UC)Anti-tumor necrosis factor (TNF) antibodiesBiologicalsSmall moleculesAdhesion molecule blockersVedolizumabUstekinumabTofacitinib

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Gastroenterology and HepatologyAcademic Medical CenterAmsterdamThe Netherlands
  2. 2.Robarts Clinical TrialsEuropean DivisionAmsterdamThe Netherlands
  3. 3.Department of GastroenterologyAmsterdamThe Netherlands